Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5697075 | Brachytherapy | 2017 | 11 Pages |
Abstract
BT and GKRS for choroidal melanoma have different physical dose and BED distributions with potentially unique clinical consequences. Using published institutional prescriptive practices, neither modality is uniformly favored, although COMS BT delivers higher physical doses and BEDs to tumors. These results suggest that lowering the physical prescription dose for COMS BT to more closely match the BED of GKRS might maintain equivalent tumor control with less potential morbidity.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Daniel Gorovets, Nolan L. Gagne, Christopher S. Melhus,